Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-004 Immunotherapy in HIV-1 Infected Subjects on ART
NCT00672191Phase 2Completed
- Sponsor
- Argos Therapeutics
- Start
- Feb 2008
- Primary completion
- Aug 2010
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of rocapuldencel-T in human immunodeficiency virus infection (HIV), sponsored by Argos Therapeutics. Started Feb 2008; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00672191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672191.